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Dear Editor, 
The colorectal cancer is the forth prevalent cancer 
worldwide. The incidence and mortality of colorectal 
cancer (CRC) in men and women has been estimated 
more than 1.233 million cases and nearly 610000 
deaths
  annually respectively
.1  It is also the forth 
prevalent cancer in Iran.
2 The CRC occurrence is cor-
related with genetic and non-genetic factors such as 
missense and non-missense mutations in a tumor sup-
pressor P53 gene.
3 It is known that most of point mu-
tations happen in exons 5 to 8 of the P53 gene with 
different prevalence in different regions.
4 Many stud-
ies showed that the frequency of P53 mutation is be-
tween 43% and 50% in CRC patients.
5Therefore, de-
tection of such mutations would be very important for 
any successful chemo-radiotherapy measure. The pre-
sent study aimed to detect and characterize different 
mutations in exons 5 and 6 of the P53 gene in patients 
with CRC in Isfahan, central Iran.  
Sixty one 62.4±9 years patients who were admit-
ted in some hospitals in Isfahan mainly Al-Zahra 
Hospital were enrolled. An ethical written agreement 
was provided and their samples were blindly used in 
the examinations. Both healthy, as control, and tu-
moral tissues, as samples, were taken and their DNA 
samples were obtained using phenol chloroform. The 
exons 5 and 6 of the P53 gene were amplified by pol-
ymerase chain reaction (PCR) using following de-
signed primers: (5´ TGTTCACTTGTGCCCTGACT 
3´, 5´ GGAGGGCCACTGACAACCA3´). 
The length of exons 5 and 6 were designed to have 
489bp.
6 Single stranded conformation polymorphism 
(SSCP) analysis and subsequently sequencing was 
performed for each PCR and electrophoresis product. 
To determine any significant difference, data were 
analyzed using Fisher Exact test. 
Sixty one samples were used of which 15 (25%) 
were females and 46 (75%) were males. Fourteen 
samples were positive (12 males and 2 females) 
among them, 3 cases had more than one mutation 
resulting in 19 point mutations of which 17 were 
missense and 2 were nonsense. There was a signifi-
cant (p=0.032) difference between the stage of   
tumor and the presence of the mutation. However, 
no significant difference was observed between mu-
tations and their locations in distal or proximal co-
lon. There was a consistency between the results of 
sequencing and PCR-SSCP examination.  Yamashita 
et al. found similar results in 6 patients with CRC 
out of 20 subjects in Sindaie, Japan.
7 However, Pan 
et al. reported only one mutation out of 97 cases 
with rectal carcinoma.
6 Similar to our results, most 
studies showed more frequent mutations in proximal 
colon compared with distal colon.
8 This may be due 
to presence of more concentrated toxic substances in 
the distal region based on dietary habits having more 
fast foods.
9  
To the best of our knowledge, our findings are the 
first report for the presence of point mutation in exons 
5 and 6 in CRC patients in Isfahan, central Iran. We 
also observed higher rate of mutations in males com-
pared to females. As some other researchers have also 
suggested, we can assume that males are more ex-
posed to the risk factors of CRC.
10 Further studies are 
required with a larger sample size to determine the 
different risk factors, possible interactions between 
suppressor genes and their related markers in CRC 
patients to help to find more efficient preventive and 
therapeutic strategies.  
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